跳至主要内容
临床试验/NCT01835860
NCT01835860已完成2 期

Prostatic Artery Embolization for Benign Prostatic Hyperplasia

Saskatchewan Health Authority - Regina Area2 个研究点 分布在 1 个国家目标入组 13 人开始时间: 2013年3月1日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
13
试验地点
2
主要终点
Change from baseline in symptom severity at 1, 3, 6 and 12 months follow-up, as measured by International prostate symptoms score (IPSS).

研究概览

简要总结

To evaluate whether Prostatic Artery Embolization (PAE) might be an effective alternative treatment option for benign prostatic hyperplasia (BPH), in comparison to current gold standard surgical treatment- Transurethral Resection of Prostate (TURP).

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

性别
Male
接受健康志愿者

入选标准

  • Moderate to severe lower urinary tract symptoms (i.e. International prostate symptom score IPSS>8) who are bothered by their symptoms (i.e., interfere with the daily activities of living)
  • Urinary retention (related to BPH) leading to catheterization.
  • Refractory to medical treatment or patient is not willing to consider medical treatment
  • Pre trans-urethral resection of prostate (TURP) to reduce the size of prostate gland if prostate is too big for TURP surgery.

排除标准

  • Mild symptoms (IPSS <8)
  • Moderate to severe lower urinary tract symptoms (i.e. IPSS>8) who are not bothered by their symptoms (i.e., symptoms do not interfere with the daily activities of living).
  • Suspected malignancy.
  • Any of the following clearly related to BPH- bladder stones, recurrent UTIs, and renal insufficiency.
  • Advanced atherosclerosis and unsuitable vascular access.
  • Allergy to intravenous contra

结局指标

主要结局

Change from baseline in symptom severity at 1, 3, 6 and 12 months follow-up, as measured by International prostate symptoms score (IPSS).

时间窗: 1, 3, 6 and 12 months

次要结局

未报告次要终点

研究者

发起方
Saskatchewan Health Authority - Regina Area
申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验